title: Long-term effect of urokinase therapy in IgA nephropathy.
abstract: Effects of urokinase (UK) therapy in patients with moderate to advanced degrees of IgA nephropathy (IgAN) were examined. Twenty-seven patients were treated by "two weeks" UK administration, 14 patients were treated by "consecutive" UK administration and 16 patients were treated by antiplatelet drugs. There were marked improvements in urinary protein concentration, serum creatinine and blood urea nitrogen after UK therapy, especially in patients treated by "consecutive" UK administration which was performed by "single shot" UK injection. Clinical prognosis was favorable in patients treated by UK administration compared with those given antiplatelet treatment. It was concluded that "consecutive" UK administration might be useful for treatment of IgAN with moderate to advanced renal injuries.
authors.affiliation: Department of Internal Medicine, School of Medicine, Tokai University, Isehara City, Kanagawa-ken, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Miura
authors.forename: M
authors.initials: M
authors.lastname: Endoh
authors.forename: Y
authors.initials: Y
authors.lastname: Nomoto
authors.forename: H
authors.initials: H
authors.lastname: Sakai
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008134:Long-Term Care; D008297:Male; D011379:Prognosis; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D012720:Severity of Illness Index; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D003404:Creatinine; D014568:Urokinase-Type Plasminogen Activator